We currently offer a dedicated Orforglipron-related product portfolio, designed to support early development, scale-up, and commercial readiness
Russ Chem Bull
Ongoing research continues to evaluate the broader role of this peptide in complex cellular environments, including its potential interactions with receptor-mediated pathways, extracellular signaling systems, and coordinated biological responses under controlled laboratory conditions

Neurological: convulsions, increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment, vertigo, headache Endocrine: menstrual irregularities, development of cushingoid state, suppression of fetal intrauterine or childhood growth, lack of secondary response of the adrenal cortex or pituitary gland, particularly in situations of stress such as trauma, surgery or illness, decreased carbohydrate tolerance, manifestations of latent diabetes mellitus, increased requirements of insulin or oral hypoglycemic agents in diabetic patients Ophtalmic: posterior subcapsular cataracts, increased intraocular pressure, glaucoma, exophthalmos Metabolic: negative nitrogen balance due to protein catabolism Psychiatric: euphoria, mood swings, severe depression to frank psychotic manifestations, personality changes, hyperirritability, insomnia Others: anaphylactoid or hypertensive reactions and hypotension or shock-like reaction Cyanocobalamin and hydroxocobalamin: hypervitaminosis and side effects were not observed with their use Dosage and administration Adults Coated tablets: 1 coated tablet 2 times a day
